市場調査レポート

商品コード

1397048

腫瘍アブレーション市場：技術別、治療別、用途別：世界の機会分析と産業予測、2022-2032年

Tumor Ablation Market By Technology, By Treatment, By Application : Global Opportunity Analysis and Industry Forecast, 2022-2032

出版日: 2023年10月31日 | 発行: Allied Market Research

| ページ情報: 英文 240 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

腫瘍アブレーション市場は、2022年に14億1,385万米ドルと評価され、2032年には50億3,244万米ドルに達すると推定され、2022年から2032年までのCAGRは13.5％を示します。

腫瘍アブレーション技術は低侵襲技術とも呼ばれ、腎臓、骨、肝臓、肺の腫瘍治療に用いられます。熱を利用して特定の腫瘍細胞を標的にします。針状の器具に熱を発生させる成分を含ませ、標的とする腫瘍細胞を壊死させる。腫瘍を体外に取り出すことなく、生体内で行われます。

プローブを挿入し、精密なコンピューター断層撮影下で100℃に加熱することにより、良性腫瘍を除去する方法です。腫瘍焼灼術には、マイクロ波焼灼術、高周波焼灼術、冷凍焼灼術など、病気の診断や治療に利用できるさまざまな方法があります。アブレーション法を繰り返し使用することで、患者の痛みやリスクを軽減し、精度を高め、より幅広い種類のがんを治療することができます。

世界の腫瘍アブレーション市場の成長は、がんの有病率の増加、腫瘍アブレーションに基づく治療の高い採用率が主な要因です。さらに、サーマルアブレーションやレーザーアブレーション、不可逆的エレクトロポレーション、高密度焦点式超音波（HIFU）の登場など、技術的に進歩した腫瘍アブレーション技術の採用や出現が、市場成長に影響を与える要因となっています。アブレーション技術の使用に関する安全性の向上、高齢者人口の増加、腫瘍アブレーションに関連する継続的な研究活動を支援するための官民イニシアチブおよび資金の増加が市場成長の原動力となっています。

壊滅的で生命を脅かす可能性のある疾患であるがんは、世界中で着実に罹患率が増加しています。例えば、National Center for Health Statisticsによると。この急増は、高齢化、ライフスタイルの変化、腫瘍の早期発見を可能にする診断法の改善など、いくつかの要因に起因しています。腫瘍アブレーション術は、大がかりな手術を必要とせずにがん組織を破壊できることから、腫瘍学の分野で大きな注目を集めています。

さらに、腫瘍アブレーション技術は、手術の適応とならない患者や、進行がんの症状を緩和するための緩和的選択肢として利用されることも多いです。がんの有病率の増加は、腫瘍アブレーション術の需要を高めるだけでなく、これらの治療法の有効性と利用しやすさを高めるための継続的な研究開発努力も刺激します。その結果、腫瘍アブレーション術市場における技術革新が促進され、先進技術や改良された装置のイントロダクションがもたらされ、市場の成長をさらに後押ししています。このように、がんの有病率の増加は市場の成長を促進すると予想されます。

さらに、腫瘍アブレーションに基づく治療法の採用率の高さが、腫瘍アブレーション市場の成長の主な促進要因として浮上しています。ラジオ波焼灼術（RFA）、マイクロ波焼灼術、冷凍アブレーションなどの腫瘍焼灼術は、肝臓腫瘍、肺腫瘍、腎臓腫瘍、骨腫瘍などさまざまな種類の腫瘍の治療に有効であるため、近年大きな人気を集めています。腫瘍アブレーション術は、従来の外科的方法と比較していくつかの明確な利点があります。低侵襲であるため、切開創が小さいか、場合によっては切開創が全くないです。その結果、回復時間の短縮、入院期間の短縮、術後合併症の減少につながり、患者にとってもヘルスケアプロバイダーにとっても魅力的な選択肢となります。

例えば、国立医学図書館による2021年の報告によると、経皮的アブレーションは安全で手術とほぼ同等の効果があり、通常、単発の肝細胞がんに対してはより低費用で、より短い入院期間で済むと報告されています。さらに、技術と画像診断の進歩により、腫瘍アブレーション術の精度と正確性が大幅に向上しました。超音波、CTスキャン、MRIなどのリアルタイムの画像ガイダンスにより、医療専門家は切除プロセス中に腫瘍を正確に狙い撃ちしてモニターすることができ、健康な周囲の臓器や組織を温存しながらがん組織を徹底的に破壊することができます。このため、腫瘍アブレーションに基づく治療法の採用が急増し、市場の成長に大きく寄与すると予想されます。

しかし、腫瘍アブレーション治療に伴う副作用が市場の成長を抑制する可能性があります。さらに、腫瘍アブレーションの研究開発活動の活発化は、市場に大きな成長機会をもたらすと期待されています。腫瘍アブレーション市場は、技術、治療、用途、地域によって区分されます。技術別では、高周波アブレーション、マイクロ波アブレーション、冷凍アブレーション、不可逆的エレクトロポレーションアブレーション、その他に分類されます。治療法別では、外科的アブレーション、腹腔鏡下アブレーション、経皮的アブレーションに分類されます。用途別では、腎臓がん、肝臓がん、乳がん、肺がん、前立腺がん、骨がんに分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（米国、カナダ、メキシコ）で分析される、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他アジア太平洋地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他欧州地域）で分析されています。世界の腫瘍アブレーション市場で事業を展開する主な主要企業は、Medtronic plc、Boston Scientific Corporation、Smith and Nephew PLC、Integra LifeSciences Holding Corporation、AngioDynamics Inc、HealthTronics, Inc、Bioventus（Misonix Inc）、Johnson and Johnson、ConMed Corporation、Olympus Corporationです。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 世界のがん有病率の増加。
  - 低侵襲の腫瘍アブレーション技術に対する需要の増加
- 抑制要因
  - 腫瘍アブレーション治療に伴う副作用
- 機会
  - 腫瘍アブレーションの研究開発活動の活発化

第4章腫瘍アブレーション市場：技術別

概要
高周波アブレーション
マイクロ波アブレーション
冷凍アブレーション
非可逆的エレクトロポレーションアブレーション
その他のアブレーション技術

第5章腫瘍アブレーション市場：治療別

概要
外科的アブレーション
腹腔鏡下アブレーション
経皮的アブレーション

第6章腫瘍アブレーション市場：用途別

概要
腎臓がん
肝臓がん
乳がん
肺がん
前立腺がん
骨がん

第7章腫瘍アブレーション市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- オーストラリア
- インド
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Medtronic plc
Boston Scientific Corporation
Smith & Nephew plc
AngioDynamics, Inc.
HealthTronics, Inc.
Bioventus LLC
Johnson & Johnson
ConMed Corporation
Olympus Corporation
Integra LifeSciences Holdings Corporation

図表

LIST OF TABLES

TABLE 01. GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 02. TUMOR ABLATION MARKET FOR RADIOFREQUENCY ABLATION, BY REGION, 2022-2032 ($MILLION)
TABLE 03. TUMOR ABLATION MARKET FOR MICROWAVE ABLATION, BY REGION, 2022-2032 ($MILLION)
TABLE 04. TUMOR ABLATION MARKET FOR CRYOABLATION, BY REGION, 2022-2032 ($MILLION)
TABLE 05. TUMOR ABLATION MARKET FOR IRREVERSIBLE ELECTROPORATION ABLATION, BY REGION, 2022-2032 ($MILLION)
TABLE 06. TUMOR ABLATION MARKET FOR OTHER ABLATION TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 08. TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022-2032 ($MILLION)
TABLE 09. TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY REGION, 2022-2032 ($MILLION)
TABLE 10. TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 12. TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 13. TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 14. TUMOR ABLATION MARKET FOR BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 15. TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 16. TUMOR ABLATION MARKET FOR PROSTATE CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 17. TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 18. TUMOR ABLATION MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 23. U.S. TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 24. U.S. TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 25. U.S. TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. CANADA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 27. CANADA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 28. CANADA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. MEXICO TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 30. MEXICO TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 31. MEXICO TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 32. EUROPE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 33. EUROPE TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 34. EUROPE TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. EUROPE TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 36. GERMANY TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 37. GERMANY TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 38. GERMANY TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. FRANCE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 40. FRANCE TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 41. FRANCE TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. UK TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 43. UK TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 44. UK TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 45. ITALY TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 46. ITALY TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 47. ITALY TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. SPAIN TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 49. SPAIN TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 50. SPAIN TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. REST OF EUROPE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 52. REST OF EUROPE TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 53. REST OF EUROPE TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 55. ASIA-PACIFIC TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 56. ASIA-PACIFIC TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 57. ASIA-PACIFIC TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 58. JAPAN TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 59. JAPAN TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 60. JAPAN TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. CHINA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 62. CHINA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 63. CHINA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. INDIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 68. INDIA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 69. INDIA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 70. SOUTH KOREA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 71. SOUTH KOREA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 72. SOUTH KOREA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. LAMEA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 77. LAMEA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 78. LAMEA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 79. LAMEA TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 80. BRAZIL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 81. BRAZIL TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 82. BRAZIL TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 83. SAUDI ARABIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 84. SAUDI ARABIA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 85. SAUDI ARABIA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 86. SOUTH AFRICA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 87. SOUTH AFRICA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 88. SOUTH AFRICA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 89. REST OF LAMEA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 90. REST OF LAMEA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
TABLE 91. REST OF LAMEA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. MEDTRONIC PLC: KEY EXECUTIVES
TABLE 93. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 94. MEDTRONIC PLC: PRODUCT SEGMENTS
TABLE 95. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 96. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
TABLE 97. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 98. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
TABLE 99. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
TABLE 100. SMITH & NEPHEW PLC: KEY EXECUTIVES
TABLE 101. SMITH & NEPHEW PLC: COMPANY SNAPSHOT
TABLE 102. SMITH & NEPHEW PLC: PRODUCT SEGMENTS
TABLE 103. SMITH & NEPHEW PLC: PRODUCT PORTFOLIO
TABLE 104. ANGIODYNAMICS, INC.: KEY EXECUTIVES
TABLE 105. ANGIODYNAMICS, INC.: COMPANY SNAPSHOT
TABLE 106. ANGIODYNAMICS, INC.: PRODUCT SEGMENTS
TABLE 107. ANGIODYNAMICS, INC.: PRODUCT PORTFOLIO
TABLE 108. ANGIODYNAMICS, INC.: KEY STRATERGIES
TABLE 109. HEALTHTRONICS, INC.: KEY EXECUTIVES
TABLE 110. HEALTHTRONICS, INC.: COMPANY SNAPSHOT
TABLE 111. HEALTHTRONICS, INC.: PRODUCT SEGMENTS
TABLE 112. HEALTHTRONICS, INC.: PRODUCT PORTFOLIO
TABLE 113. BIOVENTUS LLC: KEY EXECUTIVES
TABLE 114. BIOVENTUS LLC: COMPANY SNAPSHOT
TABLE 115. BIOVENTUS LLC: PRODUCT SEGMENTS
TABLE 116. BIOVENTUS LLC: PRODUCT PORTFOLIO
TABLE 117. BIOVENTUS LLC: KEY STRATERGIES
TABLE 118. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 119. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 120. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 121. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 122. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 123. CONMED CORPORATION: KEY EXECUTIVES
TABLE 124. CONMED CORPORATION: COMPANY SNAPSHOT
TABLE 125. CONMED CORPORATION: PRODUCT SEGMENTS
TABLE 126. CONMED CORPORATION: PRODUCT PORTFOLIO
TABLE 127. OLYMPUS CORPORATION: KEY EXECUTIVES
TABLE 128. OLYMPUS CORPORATION: COMPANY SNAPSHOT
TABLE 129. OLYMPUS CORPORATION: PRODUCT SEGMENTS
TABLE 130. OLYMPUS CORPORATION: PRODUCT PORTFOLIO
TABLE 131. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
TABLE 132. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
TABLE 133. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT SEGMENTS
TABLE 134. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
TABLE 135. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. TUMOR ABLATION MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF TUMOR ABLATION MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN TUMOR ABLATION MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN TUMOR ABLATION MARKET (2022-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. LOW BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL TUMOR ABLATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR RADIOFREQUENCY ABLATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR MICROWAVE ABLATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR CRYOABLATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR IRREVERSIBLE ELECTROPORATION ABLATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR OTHER ABLATION TECHNOLOGIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. TUMOR ABLATION MARKET, BY TREATMENT, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. TUMOR ABLATION MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR LIVER CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR BREAST CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR LUNG CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR PROSTATE CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR BONE CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 28. TUMOR ABLATION MARKET BY REGION, 2022 AND 2032(%)
FIGURE 29. U.S. TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 30. CANADA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 31. MEXICO TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 32. GERMANY TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 33. FRANCE TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 34. UK TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 35. ITALY TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 36. SPAIN TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF EUROPE TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 38. JAPAN TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 39. CHINA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 40. AUSTRALIA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 41. INDIA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 42. SOUTH KOREA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 43. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 44. BRAZIL TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 45. SAUDI ARABIA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 46. SOUTH AFRICA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 47. REST OF LAMEA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
FIGURE 48. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 52. COMPETITIVE DASHBOARD
FIGURE 53. COMPETITIVE HEATMAP: TUMOR ABLATION MARKET
FIGURE 54. TOP PLAYER POSITIONING, 2022
FIGURE 55. MEDTRONIC PLC: NET SALES, 2021-2023 ($MILLION)
FIGURE 56. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 57. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 58. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
FIGURE 59. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 60. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 61. SMITH & NEPHEW PLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 62. SMITH & NEPHEW PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 63. SMITH & NEPHEW PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. ANGIODYNAMICS, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 65. ANGIODYNAMICS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 66. ANGIODYNAMICS, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 67. BIOVENTUS LLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 68. BIOVENTUS LLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 69. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 70. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 71. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 72. CONMED CORPORATION: NET SALES, 2020-2022 ($MILLION)
FIGURE 73. CONMED CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 74. OLYMPUS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 75. OLYMPUS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 76. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 77. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 78. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A17208

The tumor ablation market was valued at $1,413.85 million in 2022 and is estimated to reach $5,032.44 million by 2032, exhibiting a CAGR of 13.5% from 2022 to 2032. Tumor ablation techniques, also referred to as minimally invasive technology, are used to treat tumors of kidney, bones, liver, and lungs. They use heat to target a specific tumor cell. It is a needle-like device with a heat-generating component that leads to cellular necrosis of targeted tumor cell. It is performed in-vivo, without taking tumors out of the body.

The method eliminates benign tumors by inserting a probe and heating it to 100 degrees Celsius under precise computer tomography. There are different methods available for tumor ablation such as microwave ablation, radiofrequency ablation, cryoablation, and others that can be used for disease diagnosis and treatment. Repeated use of ablation methods helps reduce patient's pain and risk while increasing accuracy and treating a broader type of cancer.

The growth of the global tumor ablation market is majorly driven by increase in prevalence of cancer, and high adoption of the tumor ablation-based treatments. Moreover, adoption and emergence of technologically advanced tumor ablation techniques including the advent of thermal and laser ablation, irreversible electroporation, and high-intensity focused ultrasound (HIFU) are the factors that influence the market growth. Increase in safety regarding use of ablation techniques, increase in geriatric population, and increase in public-private initiatives & funding to support ongoing research activities related to tumor ablation drive the market growth.

Cancer, a devastating and potentially life-threatening disease, has been steadily increasing in incidence across the globe. For instance, according to the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S. This surge can be attributed to several factors, including an aging population, lifestyle changes, and improved diagnostics that enable earlier detection of tumors. Tumor ablation techniques have gained significant prominence in the field of oncology due to their ability to destroy cancerous tissue without the need for extensive surgeries.

Additionally, tumor ablation techniques are often utilized for patients who are not candidates for surgery or as a palliative option to relieve symptoms in advanced cancer cases. The increasing prevalence of cancer not only drives the demand for tumor ablation procedures but also stimulates ongoing research and development efforts to enhance the efficacy and accessibility of these treatments. This, in turn, fosters innovation in the tumor ablation market, leading to the introduction of advanced technologies and improved devices, which further boosts market growth. Thus, the rise in prevalence of cancer is expected to drive the growth of the market.

Furthermore, the high adoption of tumor ablation-based treatments has emerged as a major driving factor for the growth of the tumor ablation market. Tumor ablation techniques, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have gained significant popularity in recent years due to their effectiveness in treating various types of tumors, including liver, lung, kidney, and bone tumors. Tumor ablation procedures offer several distinct advantages over traditional surgical methods. They are minimally invasive, which means they involve smaller incisions or, in some cases, no incisions at all. This results in shorter recovery times, reduced hospital stays, and lower post-operative complications, making them more attractive options for both patients and healthcare providers.

For instance, according to a 2021 report by the National Library of Medicine, it was reported that percutaneous ablation is safe and nearly as efficacious as surgery, usually requiring a lower cost and shorter hospital stay for single hepatocellular carcinoma. In addition, advancements in technology and imaging have greatly improved the precision and accuracy of tumor ablation procedures. Real-time imaging guidance, such as ultrasound, CT scans, or MRI, allows medical professionals to precisely target and monitor the tumor during the ablation process, ensuring thorough destruction of the cancerous tissue while sparing healthy surrounding organs and tissues. Thus, the surge in adoption of tumor ablation-based treatments is expected to significantly contribute to the growth of the market.

However, side-effects associated with tumor ablation treatment might restrain the growth of the market. Moreover, a rise in research and development activities for tumor ablation is expected to present significant growth opportunities to the market. The tumor ablation market is segmented on the basis of technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. By treatment, it is classified into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, it is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer and bone cancer. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major key players that operate in the global tumor ablation market are Medtronic plc, Boston Scientific Corporation, Smith and Nephew PLC, Integra LifeSciences Holding Corporation, AngioDynamics Inc, HealthTronics, Inc, Bioventus (Misonix Inc), Johnson and Johnson, ConMed Corporation and Olympus Corporation.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tumor ablation market analysis from 2022 to 2032 to identify the prevailing tumor ablation market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the tumor ablation market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global tumor ablation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Market share analysis of players by products/segments
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Average Selling Price Analysis / Price Point Analysis
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Technology

Radiofrequency Ablation
Microwave Ablation
Cryoablation
Irreversible Electroporation Ablation
Other Ablation Technologies

By Treatment

Surgical Ablation
Laparoscopic Ablation
Percutaneous Ablation

By Application

Kidney Cancer
Liver Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
Bone Cancer

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Olympus Corporation
AngioDynamics, Inc.
Bioventus LLC
Johnson & Johnson
Medtronic plc
ConMed Corporation
Smith & Nephew plc
Integra LifeSciences Holdings Corporation
HealthTronics, Inc.
Boston Scientific Corporation

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of cancers across the globe.
  - 3.4.1.2. Increase in demand for minimally invasive tumor ablation techniques.
- 3.4.2. Restraints
  - 3.4.2.1. Side-effects associated with tumor ablation treatment.
- 3.4.3. Opportunities
  - 3.4.3.1. Rise in research and development activities for tumor ablation.

CHAPTER 4: TUMOR ABLATION MARKET, BY TECHNOLOGY

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Radiofrequency Ablation
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Microwave Ablation
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Cryoablation
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Irreversible Electroporation Ablation
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Other Ablation Technologies
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: TUMOR ABLATION MARKET, BY TREATMENT

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Surgical Ablation
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Laparoscopic Ablation
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Percutaneous Ablation
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: TUMOR ABLATION MARKET, BY APPLICATION

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Kidney Cancer
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Liver Cancer
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Breast Cancer
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
6.5. Lung Cancer
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country
6.6. Prostate Cancer
- 6.6.1. Key market trends, growth factors and opportunities
- 6.6.2. Market size and forecast, by region
- 6.6.3. Market share analysis by country
6.7. Bone Cancer
- 6.7.1. Key market trends, growth factors and opportunities
- 6.7.2. Market size and forecast, by region
- 6.7.3. Market share analysis by country

CHAPTER 7: TUMOR ABLATION MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Technology
- 7.2.3. Market size and forecast, by Treatment
- 7.2.4. Market size and forecast, by Application
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Technology
  - 7.2.5.1.2. Market size and forecast, by Treatment
  - 7.2.5.1.3. Market size and forecast, by Application
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Technology
  - 7.2.5.2.2. Market size and forecast, by Treatment
  - 7.2.5.2.3. Market size and forecast, by Application
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Technology
  - 7.2.5.3.2. Market size and forecast, by Treatment
  - 7.2.5.3.3. Market size and forecast, by Application
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Technology
- 7.3.3. Market size and forecast, by Treatment
- 7.3.4. Market size and forecast, by Application
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Technology
  - 7.3.5.1.2. Market size and forecast, by Treatment
  - 7.3.5.1.3. Market size and forecast, by Application
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Technology
  - 7.3.5.2.2. Market size and forecast, by Treatment
  - 7.3.5.2.3. Market size and forecast, by Application
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Technology
  - 7.3.5.3.2. Market size and forecast, by Treatment
  - 7.3.5.3.3. Market size and forecast, by Application
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Technology
  - 7.3.5.4.2. Market size and forecast, by Treatment
  - 7.3.5.4.3. Market size and forecast, by Application
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Technology
  - 7.3.5.5.2. Market size and forecast, by Treatment
  - 7.3.5.5.3. Market size and forecast, by Application
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Technology
  - 7.3.5.6.2. Market size and forecast, by Treatment
  - 7.3.5.6.3. Market size and forecast, by Application
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Technology
- 7.4.3. Market size and forecast, by Treatment
- 7.4.4. Market size and forecast, by Application
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Technology
  - 7.4.5.1.2. Market size and forecast, by Treatment
  - 7.4.5.1.3. Market size and forecast, by Application
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Technology
  - 7.4.5.2.2. Market size and forecast, by Treatment
  - 7.4.5.2.3. Market size and forecast, by Application
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Market size and forecast, by Technology
  - 7.4.5.3.2. Market size and forecast, by Treatment
  - 7.4.5.3.3. Market size and forecast, by Application
  - 7.4.5.4. India
  - 7.4.5.4.1. Market size and forecast, by Technology
  - 7.4.5.4.2. Market size and forecast, by Treatment
  - 7.4.5.4.3. Market size and forecast, by Application
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Technology
  - 7.4.5.5.2. Market size and forecast, by Treatment
  - 7.4.5.5.3. Market size and forecast, by Application
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Technology
  - 7.4.5.6.2. Market size and forecast, by Treatment
  - 7.4.5.6.3. Market size and forecast, by Application
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Technology
- 7.5.3. Market size and forecast, by Treatment
- 7.5.4. Market size and forecast, by Application
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Technology
  - 7.5.5.1.2. Market size and forecast, by Treatment
  - 7.5.5.1.3. Market size and forecast, by Application
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Technology
  - 7.5.5.2.2. Market size and forecast, by Treatment
  - 7.5.5.2.3. Market size and forecast, by Application
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Technology
  - 7.5.5.3.2. Market size and forecast, by Treatment
  - 7.5.5.3.3. Market size and forecast, by Application
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Technology
  - 7.5.5.4.2. Market size and forecast, by Treatment
  - 7.5.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Medtronic plc
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Boston Scientific Corporation
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Smith & Nephew plc
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. AngioDynamics, Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. HealthTronics, Inc.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
9.6. Bioventus LLC
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Johnson & Johnson
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. ConMed Corporation
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Olympus Corporation
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Integra LifeSciences Holdings Corporation
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

腫瘍アブレーション市場：技術別、治療別、用途別：世界の機会分析と産業予測、2022-2032年

Tumor Ablation Market By Technology, By Treatment, By Application : Global Opportunity Analysis and Industry Forecast, 2022-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章腫瘍アブレーション市場：技術別

第5章腫瘍アブレーション市場：治療別

第6章腫瘍アブレーション市場：用途別

第7章腫瘍アブレーション市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Technology

By Treatment

By Application

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: TUMOR ABLATION MARKET, BY TECHNOLOGY

CHAPTER 5: TUMOR ABLATION MARKET, BY TREATMENT

CHAPTER 6: TUMOR ABLATION MARKET, BY APPLICATION

CHAPTER 7: TUMOR ABLATION MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

腫瘍アブレーション市場：技術別、治療別、用途別：世界の機会分析と産業予測、2022-2032年

Tumor Ablation Market By Technology, By Treatment, By Application : Global Opportunity Analysis and Industry Forecast, 2022-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 腫瘍アブレーション市場：技術別

第5章 腫瘍アブレーション市場：治療別

第6章 腫瘍アブレーション市場：用途別

第7章 腫瘍アブレーション市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Technology

By Treatment

By Application

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: TUMOR ABLATION MARKET, BY TECHNOLOGY

CHAPTER 5: TUMOR ABLATION MARKET, BY TREATMENT

CHAPTER 6: TUMOR ABLATION MARKET, BY APPLICATION

CHAPTER 7: TUMOR ABLATION MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章腫瘍アブレーション市場：技術別

第5章腫瘍アブレーション市場：治療別

第6章腫瘍アブレーション市場：用途別

第7章腫瘍アブレーション市場：地域別

第8章競争情勢

第9章企業プロファイル